Sunshine Heart (CHFS) Receiving Somewhat Critical News Coverage, Accern Reports

Media coverage about Sunshine Heart (NASDAQ:CHFS) has been trending somewhat negative this week, Accern reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sunshine Heart earned a coverage optimism score of -0.01 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.4199508450171 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news headlines that may have impacted Accern’s rankings:

Sunshine Heart (CHFS) traded up $0.31 during midday trading on Friday, reaching $3.89. 2,884,772 shares of the company’s stock traded hands, compared to its average volume of 388,486. Sunshine Heart has a fifty-two week low of $2.87 and a fifty-two week high of $137.00. The stock has a market cap of $6.99, a PE ratio of -0.03 and a beta of 2.25.

Sunshine Heart (NASDAQ:CHFS) last posted its earnings results on Tuesday, October 31st. The company reported ($4.55) earnings per share (EPS) for the quarter. Sunshine Heart had a negative return on equity of 165.61% and a negative net margin of 263.73%. equities research analysts forecast that Sunshine Heart will post -3.03 earnings per share for the current fiscal year.

Several research firms have issued reports on CHFS. Zacks Investment Research cut shares of Sunshine Heart from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. ValuEngine upgraded shares of Sunshine Heart from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 31st.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at

About Sunshine Heart

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Insider Buying and Selling by Quarter for Sunshine Heart (NASDAQ:CHFS)

Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with's FREE daily email newsletter.

Leave a Reply